United States:
FDA Determines SODIUM SULAMYD Drug Products Were Not Withdrawn For Reasons Of Safety Or Effectiveness
To print this article, all you need is to be registered or login on Mondaq.com.
In the May 13, 2015, Federal Register, FDA announced it determined
that SODIUM SULAMYD (sulfacetamide sodium) Ophthalmic Solution and
Ophthalmic Ointment were not withdrawn due to safety or
effectiveness reasons. This determination allows FDA to approve any
future or pending abbreviated new drug applications for this
product, if all other legal and regulatory requirements are
met.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
FDA Ramps Up Actions On PFAS
Holland & Knight
The U.S. Food and Drug Administration (FDA) has increased regulatory activity with regard to per- and polyfluoroalkyl substances (PFAS).
Planning For The BIOSECURE Act
Foley Hoag LLP
Bipartisan legislation moving through the U.S. House and Senate, known as the BIOSECURE Act, could limit the ability of U.S. life sciences companies...
